Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TOBiotechnology
+$0.22 today
- Market cap
- $595.76M
- Beta
- 1.48
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.74
Volume 0.16M
Average 0.05M
EPRX.TO Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 178.2% from a year ago
Net receivables stood at $663.7K at the end of Q1 FY2026, up 178.2% from a year earlier and down 1.4% from the prior quarter. Over 3 fiscal years it compounded at +76.9% a year.
Context
- Net receivables amounted to 0.5% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +178.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
Mixed currencies · from the balance sheet
- Latest · FY2025
- 673K USD
- Year-over-year change
- +194.0%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 673K | +194.0% |
| FY2024 | 2024-12-31 | 228.87K | +20.1% |
| FY2023 | 2023-12-31 | 190.61K | — |
| FY2022 | 2022-12-31 | 121.51K | -63.9% |
| FY2021 | 2021-12-31 | 337.03K | — |
Net Receivables vs competitors
How EPRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +178.2% is the highest of 8, against a peer median of -17.1%.
- Net receivables amounts to 0.5% of total assets for EPRX.TO, versus a peer median of 10.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$53.39M CAD | +6.8% | — | 10.2% | |
| Mar 2026 | CA$36.29M CAD | -31.2% | -19.1% | 3.2% | |
| Mar 2026 | $33.17M USD | -24.8% | -18.3% | 11.9% | |
| Mar 2026 | $18.71M USD | +21.1% | +146.6% | 26.1% | |
| Mar 2026 | $15.56M USD | -17.1% | -9.4% | 2.8% | |
PRN.TOProfound Medical Corp. | Mar 2026 | $9.43M USD | +58.1% | -3.8% | 12.8% |
| Mar 2026 | $663.7K USD | +178.2% | +76.9% | 0.5% | |
| Apr 2026 | CA$28K CAD | -90.2% | -24.3% | 0.1% | |
| Peer median (excluding EPRX.TO) | — | -17.1% | -13.8% | 10.2% | |
Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 20.89M | 24.74M | 19.2M | 33.1M | 80.42M |
| Short-term Investments | 9.01M | 0 | 0 | 0 | 0 |
| Net Receivables | 337.03K | 121.51K | 190.61K | 228.87K | 673K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 151.14K | 109 | 0 | 0 | (7.02K) |
| Total Current Assets | 30.6M | 25.18M | 19.8M | 34.44M | 84.94M |
| Property, Plant & Equipment (Net) | 589.07K | 695.48K | 452.97K | 424.92K | 985.33K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 31.37K | 3.37K | 6.85K | 80.76K | 64.22K |
| Total Non-current Assets | 620.44K | 698.85K | 459.82K | 505.68K | 1.05M |
| Total Assets | 31.22M | 25.88M | 20.12M | 34.94M | 85.99M |
| Account Payables | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 74.44K | 107.53K | 10.37M | 71.82K | 78.31K |
| Tax Payables | 0 | 0 | 36.16K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 3.06K | 0 | 0 |
| Other Current Liabilities | 1.4M | 1.55M | 2.73M | (1.5M) | 1.43M |
| Total Current Liabilities | 2.27M | 4.14M | 19.23M | 4.46M | 5.62M |
| Long-term Debt | 9.26M | 10.3M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 29.71K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 9.4M | 10.37M | 0 | 0 | 75.77K |
| Total Liabilities | 11.67M | 14.51M | 19.23M | 4.46M | 5.69M |
| Common Stock | 80.71M | 92.34M | 69.96M | 116.36M | 195.05M |
| Retained Earnings | (74.19M) | (97.45M) | (79.43M) | (131M) | (169.27M) |
| Accumulated OCI | 0 | 0 | (2.7M) | (5.98M) | (2.04M) |
| Other Stockholders Equity | 0 | 0 | 662.23K | 1.82M | 0 |
| Minority Interest | (833.84K) | (1.49M) | (1.32M) | (1.57M) | (1.59M) |
| Total Equity | 19.55M | 11.36M | 892.33K | 31.84M | 80.3M |
| Total Debt | 9.49M | 10.55M | 10.45M | 71.86K | 154.08K |
| Net Debt | (11.4M) | (14.19M) | (8.83M) | (33.03M) | (80.26M) |
Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.